Clarity Pharmaceuticals Ltd (CU6.AX)
AUD 4.97
(-3.87%)
AUD 4.97
(-3.87%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -43.23 Million | -27.49 Million | -13.31 Million | -7.67 Million | -6.83 Million | -3.7 Million |
| Net Income | -42.32 Million | -24.6 Million | -23.75 Million | -10.22 Million | -6.95 Million | -3.68 Million |
| Depreciation & Amortization | 153.06 Thousand | 100.51 Thousand | 46.24 Thousand | 15.62 Thousand | 16.99 Thousand | 22.01 Thousand |
| Deferred income taxes | - | -4.77 Million | -352.78 Thousand | -1.74 Million | -2.38 Million | -884.77 Thousand |
| Stock-based compensation | 4.17 Million | 1.25 Million | 1.98 Million | 2.07 Million | 1.18 Million | 522.16 Thousand |
| Change in working capital | -5.24 Million | -4.24 Million | 1.62 Million | 453.97 Thousand | -1.07 Million | -566.77 Thousand |
| Other non-cash items | 6.85 Million | 4.77 Million | 7.13 Million | 1.74 Million | 2.37 Million | 884.77 Thousand |
| Investing Cash Flow | -55.3 Million | 3.15 Million | -26.71 Million | -60.31 Thousand | -14.49 Thousand | -15.67 Thousand |
| Investments in PPE | -504 Thousand | -46.56 Thousand | -213.14 Thousand | -60.31 Thousand | -14.49 Thousand | -15.67 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -54.8 Million | 3.19 Million | -26.5 Million | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -54.8 Million | 3.19 Million | -26.5 Million | -9.5 Million | - | - |
| Financing Cash Flow | 115.21 Million | 231.58 Thousand | 86.92 Million | 10.91 Million | 8.21 Million | 5.92 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | -6.64 Million | -12.75 Thousand | -5.6 Million | - | - | - |
| Common Stock Issuance | 115.21 Million | 231.58 Thousand | 92.39 Million | 20.41 Million | 4.69 Million | 10.45 Million |
| Other Financing Activities | 20 Thousand | 12.74 Thousand | 132 Thousand | -9.5 Million | 3.52 Million | -4.52 Million |
| Accounts receivables | -2.63 Million | -3.34 Million | -3.28 Million | -712.28 Thousand | -923.92 Thousand | -689.06 Thousand |
| Accounts payables | 259.99 Thousand | 18.17 Thousand | 5 Million | 1.07 Million | -237.8 Thousand | 370.48 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.86 Million | -922.62 Thousand | -91.65 Thousand | 93.73 Thousand | 85.54 Thousand | -248.19 Thousand |
| Cash at beginning of period | 65.01 Million | 92.33 Million | 8.43 Million | 5.26 Million | 3.89 Million | 1.67 Million |
| Cash at end of period | 136.5 Million | 65.01 Million | 55.33 Million | 8.43 Million | 5.26 Million | 3.89 Million |
| Capital Expenditure | -504 Thousand | -46.56 Thousand | -213.14 Thousand | -60.31 Thousand | -14.49 Thousand | -15.67 Thousand |
| Effect of forex changes on cash | 19.55 Thousand | -5875.00 | -3160.00 | -3457.00 | 600.00 | 8671.00 |
| Net cash flow / Change in cash | 71.49 Million | -27.32 Million | 46.89 Million | 3.17 Million | 1.37 Million | 2.21 Million |
| Free Cash Flow | -43.74 Million | -27.54 Million | -13.52 Million | -7.73 Million | -6.84 Million | -3.72 Million |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -42.32 Million | -12.56 Million | -12.56 Million | -17.2 Million | -8.6 Million | -24.6 Million |
| Depreciation & Amortization | 153.06 Thousand | 50.95 Thousand | 50.95 Thousand | 51.15 Thousand | 25.58 Thousand | 100.51 Thousand |
| Deferred income taxes | - | - | - | - | - | -4.77 Million |
| Stock-based compensation | - | 2.08 Million | 2.08 Million | - | - | 1.25 Million |
| Change in working capital | -5.24 Million | -2.75 Million | -2.75 Million | - | - | -4.24 Million |
| Other non-cash items | 6.85 Million | 4.9 Million | 4.9 Million | -9.44 Million | -4.77 Million | 4.77 Million |
| Investing Cash Flow | -55.3 Million | -36.93 Million | -36.93 Million | 18.55 Million | 9.27 Million | 3.15 Million |
| Investments in PPE | -504 Thousand | -31.37 Thousand | -31.37 Thousand | -441.24 Thousand | -220.62 Thousand | -46.56 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | 3.19 Million |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -54.8 Million | -36.89 Million | -36.89 Million | 18.99 Million | 9.49 Million | 3.19 Million |
| Financing Cash Flow | 115.21 Million | 57.54 Million | 57.54 Million | 117.16 Thousand | 58.58 Thousand | 231.58 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | -12.75 Thousand |
| Common Stock Issuance | 115.21 Million | 115.09 Million | - | 117.16 Thousand | - | 231.58 Thousand |
| Other Financing Activities | - | 57.54 Million | 57.54 Million | 58.58 Thousand | 58.58 Thousand | 12.74 Thousand |
| Accounts receivables | -2.63 Million | -1.31 Million | -1.31 Million | - | - | -3.34 Million |
| Accounts payables | 259.99 Thousand | - | - | - | - | 18.17 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | -2.86 Million | -1.43 Million | -1.43 Million | - | - | -922.62 Thousand |
| Cash at beginning of period | 65.01 Million | 37.98 Million | - | 65.01 Million | - | 92.33 Million |
| Cash at end of period | 136.5 Million | 136.5 Million | 12.36 Million | 37.98 Million | -4.01 Million | 65.01 Million |
| Capital Expenditure | -504 Thousand | -31.37 Thousand | -31.37 Thousand | -441.24 Thousand | -220.62 Thousand | -46.56 Thousand |
| Effect of forex changes on cash | - | 13.47 Thousand | 13.47 Thousand | -3698.00 | -3698.00 | -5875.00 |
| Net cash flow / Change in cash | 71.49 Million | 98.52 Million | 12.36 Million | -27.03 Million | -4.01 Million | -27.32 Million |
| Free Cash Flow | -43.74 Million | -8.29 Million | -8.29 Million | -27.14 Million | -13.57 Million | -27.54 Million |
SPLIL
DCI
MNTN-WT
GRHI
PRQR
NSA-PA